Status:
COMPLETED
Use of Ibandronate in Diabetic Patients
Lead Sponsor:
Yeouido St. Mary's Hospital
Collaborating Sponsors:
Samsung Medical Center
Seoul National University Bundang Hospital
Conditions:
Osteoporosis, Postmenopausal
Type 2 Diabetes
Eligibility:
FEMALE
55+ years
Phase:
NA
Brief Summary
The purpose of this study is to examine whether monthly oral administration of ibandronate to postmenopausal osteoporosis patients with type 2 diabetes differs in safety and efficacy compared to patie...
Detailed Description
There are two major considerations in the use of bisphosphonates in diabetic patients. * The low rate of bone turnover in diabetic patients is at risk of side effects such as excessive inhibition of ...
Eligibility Criteria
Inclusion
- age of at least 55 years at the time of screening
- postmenopausal woman
- diagnosis of osteoporosis
Exclusion
- history of osteoporosis treatment
- underlying disease (e.g., heart failure, liver disease, renal disease, or malignancy)
- the use of drugs that affect bone metabolism (e.g., steroids, immunosuppressants, gonadotropin-releasing hormone agonists, aromatase inhibitors, thiazolidinedione drugs, anticonvulsants, and antidepressants)
- history of adverse effects of bisphosphonate or difficulty taking the drug due to an inability to sit or the presence of upper gastrointestinal disease
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT05266261
Start Date
October 1 2018
End Date
January 31 2022
Last Update
March 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yeouido St.Mary's Hospital
Seoul, South Korea